What question did this study set out to answer?

To evaluate the real-world efficacy, response rates, and survival outcomes of gilteritinib combined with allogeneic haematopoietic stem cell transplantation in relapsed or refractory FLT3-mutated acute myeloid leukaemia.

August 20, 2026British Journal of HaematologyOpen Access

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

View Full Paper

Ask AI

Bookmark

To evaluate the real-world efficacy, response rates, and survival outcomes of gilteritinib combined with allogeneic haematopoietic stem cell transplantation in relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Multicentre real-world cohort study involving N=156 consecutive relapsed/refractory AML patients with FLT3-ITD or FLT3-TKD mutations treated across 25 centres.
Assessed response and survival among patients receiving gilteritinib monotherapy, consolidating alloHSCT, and post-transplant gilteritinib maintenance.
The entire cohort achieved an overall complete remission/incomplete remission (CR/CRi) rate of 45.3% and a median overall survival (OS) of 10.0 months.
Patients treated with gilteritinib alone had a 1-year OS of 34%, whereas consolidating alloHSCT increased 1-year OS to 76%–92% depending on post-transplant maintenance.
Resuming gilteritinib maintenance post-transplant achieved an 85.7% CR/CRi rate.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Multicentre cohort study demonstrates improved survival with gilteritinib bridged to stem cell transplantation in FLT3-mutated AML, highlighting its value in peri-transplant care.

Cite This Study

Kunadt et al. (2026) studied this question.

synapsesocial.com/papers/6a86b6208a91293e6a1cdcbf https://doi.org/10.1111/bjh.70735

View Full Paper

Ask AI

Bookmark

Implication

Multicentre cohort study demonstrates improved survival with gilteritinib bridged to stem cell transplantation in FLT3-mutated AML, highlighting its value in peri-transplant care.

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

Key Points

Discussion

Implication

Cite This Study

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider